Metalloproteinase inhibitors: new opportunities for the treatment of rheumatoid arthritis and osteoarthritis

Bibliography

• BLACK RA, RAUCH CT, KOZLOSKY CJ et al.: A metallopro-teinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature (1997) 385:729–733.
   PubMed Web of Science ®Google Scholar
• FINK B, MARTIN R, FLEISHMAN R, MORELAND L, SCHIFF M, BARTHON J: A Phase III trial of Entanercept vs. methotrexate (MTX) in early rheumatoid arthritis (ENBREL ERA Trail). Arthritis Rheum. (1999) 42 (Suppl. 9) :280.
   Google Scholar
• MCGHEEHAN GM, BECHERER JD, BAST-ROBERT C et al.: Regulation of tumour necrosis factor alpha processing by a metalloproteinase inhibitor. Nature (1994) 370:558–561.
   PubMed Web of Science ®Google Scholar
• PESCHON JJ et al.: An essential role for ectodomainshedding in mammalian development. Science (1998) 282:1281–1295.
   PubMed Web of Science ®Google Scholar
• ALEXOPOULOU L, PASPARAKIS M, KOLLIAS GA: Murinetransmembrane tumour necrosis factor (TNF) transgene induces arthritis by co-operative p55/p75 TNF- receptor signalling. Eur. J. Immunol. (1997) 27:2588–2592.
   PubMed Web of Science ®Google Scholar
• WILLIAMS LM, GIBBONS DL, GEARING A, MAINI RN, FELDMANN M, BRENNAN FM: Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF- receptor shedding and TNF-a processing in RA synovial membrane cell cultures. J. Clin. Invest. (1996) 97:2833–2841.
   PubMed Web of Science ®Google Scholar
• PAULUS HE, VAN DER HEIJDE DMFM, BULPITT KJ, GOLD RH: Monitoring radiographic changes in early Rheumatoid Arthritis. J. Rheumatol. (1996) 23:801–805.
   PubMed Web of Science ®Google Scholar
• PINCUS T: Long-term outcome in rheumatoid arthritis. Br. J. Rheumatol (1995) 34 (Suppl. 2) :59–73.
   Google Scholar
• SCOTT DL, ADEBAJO AO, EL-BADAWAY S, KIRWAN JR, VAN DE PUTTE LBA, VAN RIEL PLCM: Disease control-ling anti-rheumatic therapy: preventing or significantly decreasing the rate of progression of structural damage. J. Rheumatol (1994) 41:36–40.
   Google Scholar
• PUGNER KM, HOLMES JW, HIEKE K, SCOTT DL: The costs of rheumatoid arthritis: A long-term view. (In prepara-tion).
   Google Scholar
• GREES REPORT: Recommendations for the registration of drugs used in the treatment of rheumatoid arthritis. Br. J. Rheumatol. (1998) 37:211–215.
   PubMedGoogle Scholar
• VAN RIEL PLCM, VAN DER HEIJDE DMFM, NUVER-ZWART IH, VAN DE PUTTE LBA: Radiological progression in rheumatoid arthritis: results of 3 comparative trials. J. Rheumatol. (1995) 22:1797–1799.
   PubMed Web of Science ®Google Scholar
• WEINBLATT ME, TRENTHAM DE, FRASER P et al.: Long-term prospective trial of low dose methotrexate in rheumatoid arthritis. Arthritis Rheum. (1988) 31:167–175.
   PubMed Web of Science ®Google Scholar
• KREMER JM, LEE JK: A long term prospective study of the use of methotrexate in rheumatoid arthritis. Arthritis Rheum. (1988) 31:577–584.
   PubMed Web of Science ®Google Scholar
• SCHIFF M, KAINE J, SHARP J, STRAND V: X-ray analysis of 12 months treatment of active rheumatoid arthritis with leflunomide compared to placebo or methotrexate. Arthritis Rheum. (1998) 41:155.
   Google Scholar
• KIRWAN JR: The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl. J. Med. (1995) 133:142–146.
   Web of Science ®Google Scholar
• MULHERIN D, FITZGERALD 0, BRESNIHAN B: Clinical improvement and radiological deterioration in rheumatoid arthritis: evidence that the pathogenesis of synovial inflammation and articular erosion may differ. Br. J. Rheumatol. (1996) 35:1263–1268.
   PubMedGoogle Scholar
• HARDINGHAM TE: Biosynthesis, assembly and turnover of cartilage proteoglycans. In: Research Monographs in Cell and Tissue Physiology. Glavert AM (Ed.), (1988):41–52.
   Google Scholar
• PETTIPHER ER, HIGGS GA, HENDERSON B: Interleukin-1induces leukocyte infiltration and cartilage degrada-tion in the synovial joint. Proc. Natl. Acad. Sci. USA (1986) 83:8749–8753.
   PubMed Web of Science ®Google Scholar
• FELL HB, BARRATT MEJ, WELLAND H, GREEN R: The capacity of pig articular cartilage in organ culture to regenerate after breakdown induced by complement-sufficient antiserum to pig erythrocytes. Cakif Tiss. Res. (1976) 20:3–21.
   PubMed Web of Science ®Google Scholar
• BIRKENDAL-HANSEN H, MOORE WGI, BODEN MK et al.:Matrix metalloproteinases: a review. Grit. Rev. Oral Biol. (1993) 4:197–250.
   PubMedGoogle Scholar
• KRANE SM, AMENTO EP, GOLDRING MB, GOLDRING SR,STEPHENSON ML: In: Research Monographs in Cell and Tissue Physiology. Glavert AM (Ed.), Elsevier, Amsterdam, The Netherlands (1988) :179–195.
   Google Scholar
• NAGASE H: Activation mechanisms of Matrix metallo-proteinases. Biol. Chem. (1997) 378:151–160.
   PubMed Web of Science ®Google Scholar
• MURPHY G: Matrix metalloproteinases and their inhibitors. Acta Orthoped. Scand. (1995) 66\(Suppl. 266) 55–60.
   Google Scholar
• WOESSNER JF, JR.: Matrix metalloproteinases and theirinhibitors in connective tissue. FASEB (1991) 5:2145–2154.
   PubMed Web of Science ®Google Scholar
• BRINCKERHOFF CE: Joint destruction in arthritis:metalloproteinase in the spotlight. Arthritis Rheum. (1991) 34:1073–1075.
   PubMed Web of Science ®Google Scholar
• CUNNANE G, FITZGERALD 0, HUMMEL KM, GAY RE, GAYS, BRESNIHAN B: Collagenase, cathepsin B and cathepsin L gene expression in the synovial membrane of patients with early inflammatory arthritis. Rheumatology (1999) 38:38–34.
   Web of Science ®Google Scholar
• WOOLEY DE, CROSSLEY MJ, EVANSON JM: Collagenaseat sites of cartilage erosion in the rheumatoid joint. Arthritis Rheum. (1977) 20:5625–5628.
   Google Scholar
• MUDGETT JS, HUTCHINSON NI, CHARTRAIN NA et al.:Susceptibility of stromelysin-1-deficient mice to collagen-induced arthritis and cartilage destruction. Arthritis Rheum. (1998) 41:110–121.
   PubMed Web of Science ®Google Scholar
• BOTTOMLEY KM, JOHNSON WH, WALTER DS: Matrix metalloproteinase inhibitors in arthritis. J. Enzyme Inhib. (1998) 13:79–101.
   PubMed Web of Science ®Google Scholar
• SKOTNICKI JS, LEVIN JI, ZASK A, KILLAR LM: Matrixmetalloproteinase inhibitors. In: Metalloproteinases as Targets for Anti-inflammatory Drugs (Progress in Inflam-mation Research). Bradshaw D, Nixon JS, Bottomley K. (Eds.) (1999):17–58.
   Google Scholar
• MORPHY JR, MILLICAN TA, PORTER JR: Matrix metallo-proteinase inhibitors: current status. Curr. Med. Chem. (1995) 2:743–762.
   Google Scholar
• NEMUNAITIS J, POOLE C, PRIMROSE J et al.: Combinedanalysis of studies of the effects of the matrix metallo-proteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin. Cancer Res. (1998) 4:1101–1109.
   PubMed Web of Science ®Google Scholar
• PETERFY CG, DION E, MIAUX Y et al.: Comparison of MRI and X-ray for monitoring erosive changes in rheumatoid arthritis. Arthritis Rheum. (1998) 41 (Suppl. 50109.
   Google Scholar
• LEWIS EJ, BISHOP J, BOTTOMLEY KMK et al.: Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo. Br. J. Pharmacol. (1997) 121:540–546.
   PubMed Web of Science ®Google Scholar
• BREWSTER M, LEWIS EJ, WILSON KL, GREENHAM AK, BOTTOMLEY KMK: Ro 32-3555, an orally active collage-nase selective inhibitor, prevents structural damage in the STR/ORT mouse model of osteoarthritis. Arthritis Rheum. (1998) 41:1639–1644.
   PubMed Web of Science ®Google Scholar
• WOOD ND, AITKEN M, HARRIS S, KITCHENER S, MCCLEL-LAND GR, SHARP S: The tolerability and pharmacoki-netics of the cartilage protective agent (Ro32-3555) in healthy male volunteers. Br. J. Clin. Pharmacol. (1996) 42:676–77.
   Web of Science ®Google Scholar
• LOLLINI L, HALLER J, EUGUI EM et al.: Disease modifica-tion by RS-130830, a collagenase-3 selective inhibitor, in experimental osteoarthritis (OA). Arthritis Rheum. (1997) 40\(Suppl. 87):341.
   Google Scholar
• CHAU T, JOLLY G, PLYM M-J eta].: Inhibition of articular cartilage degradation in dog and guinea-pig models of osteoarthritis by the stromelysin inhibitor, BAY 12–9566. Arthritis Rheum. (1998) 41 (Suppl. 300):1605.
   Google Scholar
• SUNNDARESAN PR, SHAH A, HELLER AH: Penetration of Bay-12-9566 in synovial fluid and effect of age and gender on the pharmacokinetics of BAY 12-9566. Annual Meeting of theAmerican Society of Clinical Pharma-cology (1998):1–129.
   Google Scholar
• Script (1999) 7:2476.
   Google Scholar